Publications in collaboration with researchers from University of Texas MD Anderson Cancer Center (35)

2024

  1. Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials

    Seminars in Arthritis and Rheumatism, Vol. 65

  2. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

  3. OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments

    Seminars in Arthritis and Rheumatism, Vol. 65

  4. Surgeon preferences for self-treatment in locally advanced non–small cell lung cancer: Would we practice what we preach?

    Journal of Thoracic and Cardiovascular Surgery

  5. Targeted Treatment against Cancer Stem Cells in Colorectal Cancer

    International Journal of Molecular Sciences, Vol. 25, Núm. 11

2022

  1. Association between use of enhanced recovery after surgery protocols and postoperative complications in colorectal surgery in Europe: The EuroPOWER international observational study

    Journal of Clinical Anesthesia, Vol. 80

2021

  1. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach

    Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 3, pp. 593-600

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. Institutional factors associated with adherence to enhanced recovery protocols for colorectal surgery: Secondary analysis of a multicenter study

    Journal of Clinical Anesthesia, Vol. 74

  4. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

    The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222

  5. Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

    European Journal of Cancer, Vol. 148, pp. 382-394

  6. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials

    Cancer Medicine, Vol. 10, Núm. 17, pp. 5748-5756

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

    Lung Cancer, Vol. 150, pp. 90-96

  3. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer

    European Urology, Vol. 78, Núm. 5, pp. 652-656

  4. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

    The Lancet Oncology, Vol. 21, Núm. 5, pp. 645-654

  5. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422

2019

  1. Association analyses identify 31 new risk loci for colorectal cancer susceptibility

    Nature Communications, Vol. 10, Núm. 1

  2. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

    European Journal of Cancer, Vol. 120, pp. 54-64

  3. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

    Annals of Oncology, Vol. 30, Núm. 3, pp. 439-446